Radioactive injection targets Hard-to-Treat pancreatic tumors

NCT ID NCT07229768

Recruiting now Disease control Sponsor: Yan Xing Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a radioactive drug called 177Lu-CTR-FAPI in 4 people with advanced pancreatic cancer that has not responded to standard treatments. The drug is given intravenously every 6 weeks for up to 4 doses. Researchers are checking for safety, how much radiation reaches organs, and whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-CTR-FAPI injection (a radioactive drug that targets tumors)
What this could lead to: If it works, this could point toward a new treatment option for advanced pancreatic cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early, small trial with only 4 participants, so results may not apply broadly. The radioactive drug may cause side effects or not shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma Her2-receptor negative breast cancer malignant pancreatic neoplasm pancreatic neoplasm soft tissue sarcoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Shanghai General Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.